FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068480412> ?p ?o ?g. }

• W2068480412 endingPage "29" @default.
• W2068480412 startingPage "21" @default.
• W2068480412 abstract "Clinical development of ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) was initiated based on strong preclinical studies that showed antitumor responses in a variety of solid tumor types and established its oral bioavailability and tolerability. In phase I trials, ZD1839 was investigated in patients with a wide variety of solid tumors that commonly express epidermal growth factor receptor–tyrosine kinase. More than 250 patients with advanced refractory disease were enrolled in phase I studies; of these, 100 had non–small cell lung cancer (NSCLC). All patients had been recipients of substantial prior therapy. Intermittent and continuous dosing schedules with ZD1839 were well tolerated by these patients for up to 6 months or more. The most frequently reported adverse events were grade 1 or 2 diarrhea and grade 1 or 2 acneiform rash; these effects were reversible on discontinuation of therapy and either required no management or were easily managed. Grade 3 or 4 adverse events were rare and most were attributed to disease progression rather than being drug related. In phase I trials, the maximum tolerated dose of ZD1839 was determined to be 700 to 1000 mg/day; diarrhea was found to be the dose-limiting toxicity. Pharmacokinetic profiles supported once-daily oral dosing and indicated that biologically active plasma concentrations were achieved at the doses studied. Pharmacodynamic results in skin biopsies showed that ZD1839 produced inhibition of epidermal growth factor receptor–tyrosine kinase in these patients. Durable tumor responses and stable disease were observed with ZD1839 treatment in patients with advanced NSCLC. Symptoms related to NSCLC also appeared to improve rapidly in some patients. Prolonged time on therapy was observed for other tumor types in addition to NSCLC, including hormone-refractory prostate, colorectal, head and neck, breast, ovarian, and renal cancers. The promising phase I results observed in heavily pretreated patients with advanced NSCLC and other solid tumors have warranted investigation in phase II/III clinical trials in these populations. Phase II/III trials are being conducted in patients with advanced NSCLC. Phase II trials of ZD1839 are also being conducted in patients who have hormone-refractory prostate, breast, or colorectal cancer, as well as other solid tumors. Based on the phase I study results, once-daily oral doses of 250 mg and 500 mg, which are well below the maximum tolerated dose, were selected for further clinical investigation of ZD1839. Semin Oncol 30 (suppl 1):21:29. Copyright 2003, Elsevier Science (USA). All rights reserved." @default.
• W2068480412 created "2016-06-24" @default.
• W2068480412 creator A5064953304 @default.
• W2068480412 date "2003-02-01" @default.
• W2068480412 modified "2023-10-08" @default.
• W2068480412 title "Phase I studies of ZD1839 in patients with common solid tumors" @default.
• W2068480412 cites W1985153867 @default.
• W2068480412 cites W2005274511 @default.
• W2068480412 cites W2010174111 @default.
• W2068480412 cites W2023389550 @default.
• W2068480412 cites W2034269086 @default.
• W2068480412 cites W2049938167 @default.
• W2068480412 cites W2051120695 @default.
• W2068480412 cites W2055901820 @default.
• W2068480412 cites W2055903396 @default.
• W2068480412 cites W2062366098 @default.
• W2068480412 cites W2064047613 @default.
• W2068480412 cites W2073104464 @default.
• W2068480412 cites W2075425070 @default.
• W2068480412 cites W2088597803 @default.
• W2068480412 cites W2093281866 @default.
• W2068480412 cites W2107921263 @default.
• W2068480412 cites W2114291028 @default.
• W2068480412 cites W2126314379 @default.
• W2068480412 cites W2135836172 @default.
• W2068480412 cites W2140184327 @default.
• W2068480412 cites W2142661339 @default.
• W2068480412 cites W2167368130 @default.
• W2068480412 cites W4244120980 @default.
• W2068480412 doi "https://doi.org/10.1053/sonc.2003.50029" @default.
• W2068480412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12644981" @default.
• W2068480412 hasPublicationYear "2003" @default.
• W2068480412 type Work @default.
• W2068480412 sameAs 2068480412 @default.
• W2068480412 citedByCount "50" @default.
• W2068480412 countsByYear W20684804122013 @default.
• W2068480412 countsByYear W20684804122015 @default.
• W2068480412 countsByYear W20684804122016 @default.
• W2068480412 countsByYear W20684804122017 @default.
• W2068480412 countsByYear W20684804122019 @default.
• W2068480412 countsByYear W20684804122021 @default.
• W2068480412 countsByYear W20684804122023 @default.
• W2068480412 crossrefType "journal-article" @default.
• W2068480412 hasAuthorship W2068480412A5064953304 @default.
• W2068480412 hasConcept C111113717 @default.
• W2068480412 hasConcept C112705442 @default.
• W2068480412 hasConcept C121608353 @default.
• W2068480412 hasConcept C126322002 @default.
• W2068480412 hasConcept C143998085 @default.
• W2068480412 hasConcept C197934379 @default.
• W2068480412 hasConcept C2777288759 @default.
• W2068480412 hasConcept C2778375690 @default.
• W2068480412 hasConcept C2778570526 @default.
• W2068480412 hasConcept C2778715236 @default.
• W2068480412 hasConcept C2779438470 @default.
• W2068480412 hasConcept C71924100 @default.
• W2068480412 hasConcept C98274493 @default.
• W2068480412 hasConceptScore W2068480412C111113717 @default.
• W2068480412 hasConceptScore W2068480412C112705442 @default.
• W2068480412 hasConceptScore W2068480412C121608353 @default.
• W2068480412 hasConceptScore W2068480412C126322002 @default.
• W2068480412 hasConceptScore W2068480412C143998085 @default.
• W2068480412 hasConceptScore W2068480412C197934379 @default.
• W2068480412 hasConceptScore W2068480412C2777288759 @default.
• W2068480412 hasConceptScore W2068480412C2778375690 @default.
• W2068480412 hasConceptScore W2068480412C2778570526 @default.
• W2068480412 hasConceptScore W2068480412C2778715236 @default.
• W2068480412 hasConceptScore W2068480412C2779438470 @default.
• W2068480412 hasConceptScore W2068480412C71924100 @default.
• W2068480412 hasConceptScore W2068480412C98274493 @default.
• W2068480412 hasIssue "1" @default.
• W2068480412 hasLocation W20684804121 @default.
• W2068480412 hasLocation W20684804122 @default.
• W2068480412 hasOpenAccess W2068480412 @default.
• W2068480412 hasPrimaryLocation W20684804121 @default.
• W2068480412 hasRelatedWork W2060361110 @default.
• W2068480412 hasRelatedWork W2360693916 @default.
• W2068480412 hasRelatedWork W2415484199 @default.
• W2068480412 hasRelatedWork W2419505618 @default.
• W2068480412 hasRelatedWork W2915644342 @default.
• W2068480412 hasRelatedWork W3121096891 @default.
• W2068480412 hasRelatedWork W3166797618 @default.
• W2068480412 hasRelatedWork W4210913627 @default.
• W2068480412 hasRelatedWork W4320086256 @default.
• W2068480412 hasRelatedWork W2464739384 @default.
• W2068480412 hasVolume "30" @default.
• W2068480412 isParatext "false" @default.
• W2068480412 isRetracted "false" @default.
• W2068480412 magId "2068480412" @default.
• W2068480412 workType "article" @default.